Cameron H A, Waller P C, Ramsay L E
Angiology. 1987 Jul;38(7):549-55. doi: 10.1177/000331978703800708.
The effect of ketanserin on the symptoms of 21 patients with stable intermittent claudication was examined in a double-blind, placebo-controlled, parallel-group study. Benefit was assessed by repeated treadmill exercise tests, recording claudication and total walking times. After three months' treatment with ketanserin (mean dose 167 mg/day) there was no significant change in claudication time (mean change + 12%, 95% CI -9; + 33%) or total walking time (mean change -14%, 95% CI -47%; + 19%). The confidence intervals show that ketanserin treatment is unlikely to be associated with clinically important improvement.
在一项双盲、安慰剂对照、平行组研究中，检测了酮色林对21例稳定型间歇性跛行患者症状的影响。通过重复的跑步机运动试验评估疗效，记录跛行时间和总步行时间。用酮色林（平均剂量167毫克/天）治疗三个月后，跛行时间（平均变化+12%，95%可信区间-9；+33%）或总步行时间（平均变化-14%，95%可信区间-47%；+19%）均无显著变化。可信区间表明，酮色林治疗不太可能带来具有临床重要意义的改善。
